Merck, known as MSD outside of the United States and Canada, announced that new clinical and real-world data for the company’s 9-valent Human Papillomavirus (HPV) vaccine, Gardasil 9 (Human ...

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal ...

RAHWAY, N.J., November 12, 2024--Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at IPVC 2024.

RAHWAY, N.J., September 11, 2024--Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal ...

For children ages 9 years and older, Gardasil 9 can be given in a two-dose or three-dose schedule, depending on their ages. However, the two-dose vaccine schedule isn’t approved for adults.

Find patient medical information for Gardasil 9 (human papillomavirus 9-valent vaccine) on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings ...

Allergic reaction was a rare side effect reported in Gardasil 9’s studies. For safety reasons, you should stay at the location where you’ve received the vaccine for 15 to 30 minutes.

Gardasil 9 is approved for use in males age 9 through 45 years to prevent certain conditions, including certain cancers, caused by human papillomavirus (HPV). Some side effects may be more or less ...

Merck, known as MSD outside of the United States and Canada, at the EUROGIN 2024 HPV Congress, announced plans to initiate clinical development of a new investigational multi-valent HPV vaccine ...

Gardasil 9 is now approved for use in women and men aged 9 through 45 years. HPV causes about 36,000 cancer cases in both men and women every year in the United States, according to government data.

Merck (NYSE: MRK) announced Wednesday plans to conduct clinical trials to evaluate the efficacy and safety of a single-dose regimen of its human papillomavirus (HPV) vaccine, Gardasil 9. "In ...